Illumina, Inc.
ILMN
Positions held
Your positionsILMN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Illumina is a leader in the genomics space, with a strong competitive advantage due to its innovative sequencing technology and established market presence.
- In the most recent quarter, Illumina reported a gross margin of 66.1%, an improvement from 65.5% in the prior quarter.
- The company has a market capitalization of approximately $41.3 billion, indicating strong investor confidence and potential for growth.
- Illumina faces challenges with declining revenue growth, as evidenced by a 6% decrease in revenue compared to the prior quarter.
- The company reported a net income of -$1161 million for the year 2023, highlighting ongoing financial struggles.
- Illumina's trailing P/E ratio stands at 51.03, suggesting that the stock may be overvalued given its current earnings performance.
Fundamentals
| Market cap | $39.95B | Enterprise value | $41.31B | Trailing P/E | 49.36 | Forward P/E | 43.24 |
| PEG | 3.30 | Price / book | 14.08 | Beta | 1.42 | Dividend yield | 0.00% |
| Revenue growth | 9.4% | Earnings growth | -9.4% | Gross margin | 67.9% | Operating margin | 21.1% |
| Profit margin | 18.3% | ROE | 32.3% | ROA | 8.7% | Debt / equity | 0.89 |
| Current ratio | 1.80 | Free cash flow | $797.63M | Analyst recommendation | buy | Mean target | $232.15 |
| 52w high | $309.35 | 52w low | $88.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | — | $1.1B | $1.2B | $1.1B | $1.1B | $1.0B |
| Op margin | — | 19.2% | 18.2% | 20.9% | 20.2% | 15.8% |
| Net income | — | $134M | $334M | $150M | $235M | $131M |
| Gross margin | — | 66.1% | 65.5% | 67.6% | 65.6% | 65.6% |
| Gross profit | — | $721M | $759M | $733M | $695M | $683M |
| Operating income | — | $209M | $211M | $227M | $214M | $164M |
- Revenue -6% vs prior quarter ($1.1B vs $1.2B).
- Gross margin 66.1% (was 65.5% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.4B | $4.5B | $4.6B | — |
| Op margin | 18.8% | 13.7% | -4.9% | 7.7% | — |
| Net income | $850M | -$1.2B | -$1.2B | -$4.4B | — |
| Gross margin | 66.1% | 65.4% | 60.9% | 64.8% | — |
| Gross profit | $2.9B | $2.9B | $2.7B | $3.0B | — |
| Operating income | $817M | $600M | -$222M | $354M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Could You Have Seen The Run In Tempus AI Stock Coming?
2026-10-09 · What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing?
2026-10-08 · Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
2026-10-08 · Illumina Launches New Genomic AI Model for Rare Disease Research
2026-10-08 · Illumina releases SpliceAI2 to help advance rare disease research
2026-10-08 · Baird Adjusts Price Target on Illumina to $286 From $225
2026-10-07 · Evercore ISI Adjusts Price Target on Illumina to $290 From $225
2026-10-06 · Stocks making big moves yesterday: Harley-Davidson, Illumina, TechnipFMC, Upstart, and DraftKings
2026-10-06 · Barclays Adjusts Illumina Price Target to $200 From $160, Maintains Underweight Rating
2026-10-06 · Illumina (ILMN) Shares Skyrocket, What You Need To Know
2026-10-06 · Why PacBio (PACB) Stock Is Trading Up Today
2026-10-05 · Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Price (daily)
Full chart · RSI · MACD · patterns